SCHEMBL663034

SCHEMBL663034

Cc1c(O)cc(O)c2c1OC(c1ccccc1)CC2=O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.80
ESR2 Q92731 4/20 0.80
CYP19A1 P11511 2/20 0.75
ABCG2 Q9UNQ0 4/20 0.68
POLB P06746 3/20 0.68
CRHBP P24387 1/20 0.68
CRHR2 Q13324 1/20 0.68
CYP3A4 P08684 2/20 0.63
CYP2D6 P10635 2/20 0.63
CYP2C9 P11712 2/20 0.63
CYP2C19 P33261 2/20 0.63
ACHE P22303 1/20 0.63
ABCB1 P08183 2/20 0.63
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
MAPT P10636 2/20 0.61
CYP1A1 P04798 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP1B1 Q16678 1/20 0.61
HSD17B10 Q99714 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28130871 0.89 ESR1 (1.00) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL30269741 0.89 ESR1 (1.00) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL31551707 0.89 ESR1 (1.00) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL665265 0.87 CYP19A1 (0.84) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL27715512 0.86 PLK1 (0.68) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL22422611 0.84 ESR1 (0.73) ESR1ESR2CYP19A1ABCG2POLB
Demethoxymatteucinol SCHEMBL29204370 0.83 ABCG2 (0.64) ESR1ESR2CYP19A1ABCG2POLB
Demethoxymatteucinol SCHEMBL664144 0.83 ABCG2 (0.64) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL9063227 0.83 CYP19A1 (0.70) ESR1ESR2CYP19A1ABCG2POLB
SCHEMBL1068874 0.82 PLK1 (0.67) ESR1ESR2CYP19A1ABCG2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238274-A1 INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS NORTHWESTERN UNIVERSITY 2024-07-18 US disclosed
US-20240238274-A1 INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS NORTHWESTERN UNIVERSITY 2024-07-18 US disclosed
WO-2023004473-A1 METHODS AND COMPOUNDS FOR SKIN CONDITIONS UNIVERSITY OF THE SUNSHINE COAST (AU) 2023-02-02 WO disclosed
US-20120046353-A1 CLEISTOCALYX OPERCULATUS-DERIVED COMPOUNDS HAVING INHIBITORY ACTIVITIES AGAINST AVIAN AND SWINE INFLUENZA VIRUSES OR NOVEL INFLUENZA VIRUS CHOONG ANG VACCINE LAB. (KR) 2012-02-23 US disclosed
EP-0742012-A2 Pharmaceutical composition containing substance inhibiting HSP47 production Kureha Chemical Industry Co., Ltd. (JP) 1996-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046353-A1 CLEISTOCALYX OPERCULATUS-DERIVED COMPOUNDS HAVING INHIBITORY ACTIVITIES AGAINST AVIAN AND SWINE INFLUENZA VIRUSES OR NOVEL INFLUENZA VIRUS PIGS, CLEC4M, ENGASE ESR1 3607/4885ESR2 4084/4885CYP19A1 4094/4885
US-20240238274-A1 INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS USP19, USP24, USP2 ESR1 3016/4885ESR2 1234/4885CYP19A1 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.